Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: The PCSK 9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol ( LDL ‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin‐associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone. Methods and Results: Patients were randomly assigned to placebo, alirocumab 150 mg Q4W or 75 mg Q2W (calibrator arm), with dose adjustment to 150 mg Q2W at week (W) 12 if W8 predefined LDL ‐C target levels were not met. The primary efficacy endpoint was LDL ‐C percentage change from baseline to W24. Mean baseline LDL ‐C levels were 163.9 mg/dL (alirocumab 150 mg Q4W, n=59), 154.5 mg/dL (alirocumab 75 mg Q2W, n=116), and 158.5 mg/dL (placebo, n=58). In the alirocumab 150 mg Q4W and 75 mg Q2W groups (49.1% and 36.0% of patients received dose adjustment, respectively), least‐squares mean LDL ‐C changes from baseline to W24 were −51.7% and −53.5%, respectively (placebo [+4.7%]; both groups P <0.0001 versus placebo). In total, 63.9% and 70.3% of alirocumab‐treated patients achieved their LDL ‐C targets at W24. Treatment‐emergent adverse events occurred in 77.6% (alirocumab 150 mg Q4W), 73.0% (alirocumab 75 mg Q2W), and 63.8% (placebo) of patients, with injection‐site reactions among the most common treatment‐emergent adverse events. Conclusions: Alirocumab 150 mg Q4W can be considered in patients not on statin with inadequately controlled hypercholesterolemia as a convenient option for lowering LDL ‐C. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02023879.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationGrundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Self-citationESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“Participants rated 7 manipulations/steps to inject alirocumab/placebo (7-point scale from “not easy at all” [1] to “extremely easy” [7]), how many clicks they heard during injection, satisfaction with duration of injection (7-point scale from “extremely unsatisfied” [1] to “extremely satisfied” [7]), and the overall e…”
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596 · cited 1×
“This is because statins are known to increase PCSK9 levels, 19 which reduce duration of alirocumab effect in the setting of every 4 weeks (Q4W) dosing.”
Cited by
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Self-citationPCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Metadata
- Authors
- Stroes, E., Guyton, J. R., Lepor, N., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G., Farnier, M., Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., Hoag, G., Hove, J., Jeppesen, J., Kjærulf, J. H., Klarlund, K., Thomsen, K. K., Basart, D. C. G., Kooy, A., Liem, A., Swart, H., Troquay, R., Van Het Hof‐Wiersma, J., Viergever, P., Visseren, F., Doughty, R. N., Scott, R., Calvo, C., Díaz‐Díaz, J. L., Fuentes, F., Gil‐Extremera, B., Jericó, C., Matas Pericas, L., Mediavilla Garcia, J. D., Bolster, D. E., Koren, M., El Shahawy, M., Vardi, G., Weinstein, D., Zuzarte, K., Ginsberg, H., Robinson, J. G., Rader, D. J., Cannon, C. P., Colhoun, H., Kastelein, J. J. P., Huo, Y., Olsson, A., Waters, D., Larrey, D., Rosenson, R. S., Patriarca, P. A., Molenberghs, G., Tricoci, P., Mahaffey, K. W., Lopes, R. D., Shah, B. R., Mehta, R. H., Roe, M. T., Eapen, Z., Armaganijan, L., Bertolami, A., Leonardi, S., Kolls, B. J., Jordan, J. D., Ducrocq, G., Puymirat, E., & Mathews, R.
- Venue
- Journal of the American Heart Association
- Published
- 2016-09
- Volume
- 5
- Issue
- 9
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2518726365
- Cited by
- 102
- References
- 15
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. https://app.cochat.ai/papers/10.1161/jaha.116.003421
- The paper
- Stroes, E., Guyton, J. R., Lepor, N., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G., Farnier, M., Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., . . . Mathews, R. (2016). Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.116.003421
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.